NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE American · Drug Manufacturers - Specialty & Generic · USD

China Pharma Holdings, Inc. (CPHI) Stock Analysis

China Pharma Holdings, Inc. (CPHI) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

CPHI

$0.70

−$0.03 (−3.77%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CPHI with… →

CPHI Key Statistics

As of Oct 21, 2026
Trading
Open
$0.71
Previous Close
$0.72
Day's Range
0.69–0.73
52-Week Range
0.38–19.19
Volume
121.47K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.05
Valuation
Market Cap
$29.99M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.16
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.66
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.42
Financials (FY)
Revenue (FY)
$4.14M−8.49%
Net Income (FY)
−$3.19M
Profit marginThe share of revenue left as profit after all costs and taxes.
−114.33%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
43.02M
1-Year Return
−61.06%
Dividend and dates
Avg Volume
2.39M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CPHI closed at $0.70, −61.06% over 1 year.

China Pharma Holdings, Inc. (CPHI) has a market capitalization of $29.99M.

In fiscal 2025, CPHI reported revenue of $4.14M.

CPHI Stock Return by Calendar Year

China Pharma Holdings, Inc. (CPHI) 10-year return: what $10,000 became

1 year
$10,000 $3,894
−61.06%
5 years
$10,000 $25
−99.75%
10 years
$10,000 $66
−99.34%

If you had invested $10,000 in China Pharma Holdings, Inc. (CPHI) 10 years ago, at the close on October 21, 2016, it would have been worth $66 at the close on October 21, 2026: −99.34% in total, −39.44% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−42.40%
2025−47.39%
2024−61.67%
2023−88.00%
2022−79.17%
2021+6.67%
2020+87.50%
2019−7.69%
2018+44.44%
2017−30.77%
2016 (partial year)−13.33%

As of October 21, 2026.

CPHI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.14M−$3.19M−76.9%
2024$4.53M−$4.74M−104.6%
2023$7.01M−$3.08M−43.9%
2022$8.10M−$3.97M−49.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.14M−$131.95K−$3.09M−$3.19M−76.9%
2024$4.53M−$1.99M−$4.58M−$4.74M−104.6%
2023$7.01M−$281.09K−$2.77M−$3.08M−43.9%
2022$8.10M−$493.92K−$3.64M−$3.97M−49.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CPHI Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricCPHIDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio7.662.103.6x the median
Profit margin−114.33%−8.14%106.2 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

China Pharma Holdings, Inc. (CPHI) carries a market capitalisation of $29.99M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 215.

The most recent close on file for CPHI is $0.70, dated October 21, 2026. That is −$0.03 (−3.77%) against the previous close. The 52-week range on file runs from $0.38 to $19.19. The latest close sits 83.42% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $4.14M. Against the prior fiscal year total of $4.53M, that is a change of −8.49%. The same year closed with a net loss of $3.19M. The reported profit margin is −114.33%. That is 106.2 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are −0.42.

Across the 4 fiscal years on file, revenue moves from $8.10M in 2022 to $4.14M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.16. Measured against sales, the shares trade at 7.66 times revenue. On price-to-sales that is 3.6 times the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

The reported beta is 1.05. Daily returns over the trailing 10 years annualize to a volatility of 282.52%. Over the trailing twelve months the total return is −61.06%. Across 10 years the annualized return works out at −39.44%.

Growth & Income

The record shows no dividend for CPHI.

2026 is still running; the total return is −42.40% year to date. Across the complete calendar years on file, 2020 returned +87.50% and 2023 returned −88.00%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

China Pharma Holdings, Inc. (CPHI) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
China Pharma Holdings, Inc. CPHI $29.99M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. China Pharma Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.

Visit website →